A Mouse-Human co-clinical trial with patient-derived xenograft (PDX) models demonstrates a predictive signature for dovitinib (TKI258), an FGFR and VEGFR inhibitor,in lung squamous cell carcinomalung cancer (LSCC)

被引：0
|
作者：
Kim, Hye Ryun
Kang, Han Na
Kim, Sung Moo
Kim, Hwan
Pyo, Kyoung-Ho
Ahn, Myung-Ju
Kim, Tae Min
Cho, Byoung Chul
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-5194
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5194
引用
收藏
页数：4
相关论文
共 2 条
  • [1] Dovitinib (TKI258), a dual inhibitor of FGFR and VEGFR, induces tumor growth suppression in xenograft models of human bladder cancer
    Shi, Michael M.
    Linnartz, Ronald
    Versace, Richard
    Brueggen, Joseph
    Chatenay-Rivauday, Christian
    Stamm, Christelle
    Dugan, Margaret
    Porta, Diana Graus
    CANCER RESEARCH, 2011, 71
  • [2] Dovitinib (TKI258), a Dual Inhibitor of FGFR and VEGFR, Induces Tumor Growth Suppression in Xenograft Models of Primary Human Breast Cancer.
    Shi, M. M.
    Linnartz, R.
    Versace, R.
    Graus, Porta D.
    Kay, A.
    Dugan, M.
    CANCER RESEARCH, 2011, 71
1